logo-loader
CB2 Insights

CB2 Insights ready to move to Phase two of study with primary care physicians tool

CB2 Insights (CSE: CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver to discuss the company moving into phase 2 of the integration of their program into the Juno platform.

Sekar tells Proactive about the results of phase 1 and what they were hearing from Physicians using the system. 

Quick facts: CB2 Insights

Price: $0.13

Market: CSE
Market Cap: $10.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights named herein, including the promotion by the Company of CB2 Insights in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks in the green; CB2 Insights gets boost from...

Buds today are CB2 Insights (CSE:CBII) (OTCQB:CBIIF), Cannvas MedTech Inc (CSE:MTEC) (OTCMKTS:CANVF). Duds are Canopy Growth Corp (TSE:WEED) (NYSE:CGC), Choom (CSE:CHOO) (OTCMKTS:CHOOF).

on 07/31/2019

2 min read